TrialThe Journal of infectious diseases2022

Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.

Kanchanamala Withanage et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.